On December 14, 2020, the United Kingdom notified the WHO of the new mutant strain of the new coronavirus for the first time and named it B.1.1.7. Recently, Shanghai, Guangdong and other places have successively found B.1.1.7 mutant strains in throat swab samples imported from confirmed cases of new coronary pneumonia, which are highly similar to the mutant virus gene sequence reported in the United Kingdom. The identification of mutant strains of the new coronavirus B.1.1.7 has become one of the keys to the current epidemic prevention and control.
In order to help cope with the impact of the new coronavirus mutation on the prevention and control of the global epidemic, BACME Biotech immediately organized research and development team to quickly develop Novel Coronary Mutant Virus Indentification and Test Kit. At present, the company has successfully developed Novel Coronavirus B.1.17 Mutant Strain Nucleic Acid Test Kit.
This kit uses BACME’s Bio-patented technology "high-sensitivity nucleic acid detection technology" combined with the ARMS-qPCR detection method to design specific primers for the mutation site N501Y and the deletion mutation site HV 69-70del of the British B.1.1.7 mutant , Combined with fluorescent probes, realized single-tube multi-channel detection and discrimination of the novel coronavirus ORF1ab gene, B.1.1.7 mutation site and internal standard, and achieved rapid identification of mutant and non-mutant strains, with high sensitivity, Features such as high performance.
In the face of epidemic, we are united to overcome the difficulties and contribute the strength that our company should have.
